Grand Pharmaceutical Group Forecasts Lower Profit For 2025; TP-03 Approved in China

MT Newswires Live03-23

Grand Pharmaceutical Group (HKG:0512) said it expects HK$1.20 billion to HK$1.25 billion in attributable profit for 2025, falling from HK$2.47 billion in 2024, according to a Hong Kong bourse filing Friday.

Shares of the pharmaceutical company fell nearly 8% in late morning trade Monday.

The firm attributed the decrease to a number of factors, including a rise in marketing and promotion-related expenses during the year.

The company expects to generate HK$12 billion to HK$12.5 billion in revenue for the year, compared with HK$11.64 billion in 2024.

The company's financial results are due March 26.

Meanwhile, in a separate announcement, the firm said its TP-03 product was approved for commercialization in China.

The medicine is meant to treat an eyelid inflammation condition known as demodex blepharitis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621721797?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 13:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621721797","market":"nz","top_or_hot":-1,"title":"Grand Pharmaceutical Group Forecasts Lower Profit For 2025; TP-03 Approved in China","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CGPHF\">Grand Pharmaceutical</a> Group (HKG:0512) said it expects HK$1.20 billion to HK$1.25 billion in attributable profit for 2025, falling from HK$2.47 billion in 2024, according to a Hong Kong bourse filing Friday.</p><p>Shares of the pharmaceutical company fell nearly 8% in late morning trade Monday.</p><p>The firm attributed the decrease to a number of factors, including a rise in marketing and promotion-related expenses during the year.</p><p>The company expects to generate HK$12 billion to HK$12.5 billion in revenue for the year, compared with HK$11.64 billion in 2024.</p><p>The company's financial results are due March 26.</p><p>Meanwhile, in a separate announcement, the firm said its TP-03 product was approved for commercialization in China.</p><p>The medicine is meant to treat an eyelid inflammation condition known as demodex blepharitis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grand Pharmaceutical Group Forecasts Lower Profit For 2025; TP-03 Approved in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrand Pharmaceutical Group Forecasts Lower Profit For 2025; TP-03 Approved in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-23 13:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CGPHF\">Grand Pharmaceutical</a> Group (HKG:0512) said it expects HK$1.20 billion to HK$1.25 billion in attributable profit for 2025, falling from HK$2.47 billion in 2024, according to a Hong Kong bourse filing Friday.</p><p>Shares of the pharmaceutical company fell nearly 8% in late morning trade Monday.</p><p>The firm attributed the decrease to a number of factors, including a rise in marketing and promotion-related expenses during the year.</p><p>The company expects to generate HK$12 billion to HK$12.5 billion in revenue for the year, compared with HK$11.64 billion in 2024.</p><p>The company's financial results are due March 26.</p><p>Meanwhile, in a separate announcement, the firm said its TP-03 product was approved for commercialization in China.</p><p>The medicine is meant to treat an eyelid inflammation condition known as demodex blepharitis.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2621721797","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621721797","pubTimestamp":1774242989,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Grand Pharmaceutical Group  said it expects HK$1.20 billion to HK$1.25 billion in attributable profit for 2025, falling from HK$2.47 billion in 2024, according to a Hong Kong bourse filing Friday.Shares of the pharmaceutical company fell nearly 8% in late morning trade Monday.The firm attributed the decrease to a number of factors, including a rise in marketing and promotion-related expenses during the year.The company expects to generate HK$12 billion to HK$12.5 billion in revenue for the year, compared with HK$11.64 billion in 2024.The company's financial results are due March 26.Meanwhile, in a separate announcement, the firm said its TP-03 product was approved for commercialization in China.The medicine is meant to treat an eyelid inflammation condition known as demodex blepharitis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","00512":"远大医药"},"translate_title":"远大医药集团预测2025年利润下降；TP-03在中国获批","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9},"content_text":"Grand Pharmaceutical Group (HKG:0512) said it expects HK$1.20 billion to HK$1.25 billion in attributable profit for 2025, falling from HK$2.47 billion in 2024, according to a Hong Kong bourse filing Friday.Shares of the pharmaceutical company fell nearly 8% in late morning trade Monday.The firm attributed the decrease to a number of factors, including a rise in marketing and promotion-related expenses during the year.The company expects to generate HK$12 billion to HK$12.5 billion in revenue for the year, compared with HK$11.64 billion in 2024.The company's financial results are due March 26.Meanwhile, in a separate announcement, the firm said its TP-03 product was approved for commercialization in China.The medicine is meant to treat an eyelid inflammation condition known as demodex blepharitis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621721797","isCrawlerRequest":true}